Evidence map›Paper›PMID 37966585›Full record

ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2024

Adrenergic receptors blockade alleviates dexamethasone-induced neurotoxicity in adult male Wistar rats: Distinct effects on β-arrestin2 expression and molecular markers of neural injury.

Rasha M S M Mohamed, Enssaf Ahmad Ahmad, Dalia M Amin, Samar Ahmed Abdo, Islam A A E-H Ibrahim, Mona F Mahmoud, Shimaa Abdelaal

Open access · hybridAbstract read
In one paragraph

Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Target the Heart: A New Axis of Alzheimer's Disease Prevention.Journal of dementia and alzheimer's disease · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Rasha M S M MohamedDepartment of Clinical Pharmacology, Faculty of Medicine, Zagazig University, Zagazig, 44519, Egypt.
Enssaf Ahmad AhmadDepartment of Human Anatomy and Embryology, Faculty of Medicine, Zagazig University, Zagazig, 44519, Egypt.
Dalia M AminDepartment of Forensic Medicine and Clinical Toxicology, Faculty of Medicine, Zagazig University, Zagazig, 44519, Egypt.
Samar Ahmed AbdoDepartment of Biochemistry, Faculty of Veterinary Medicine, Zagazig University, Zagazig, 44519, Egypt.
Islam A A E-H IbrahimDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig, 44519, Egypt. eaebrahiem@pharmacy.zu.edu.eg.ORCID http://orcid.org/0000-0002-8931-465X
Mona F MahmoudDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig, 44519, Egypt.
Shimaa AbdelaalDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig, 44519, Egypt.
Zagazig University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDexamethasone-induced neurotoxicity has been previously reported. However, the molecular mechanisms are still not completely understood.

objectivesThe current work aimed to investigate the modulatory effects of α- and β-adrenergic receptors on dexamethasone-induced neurotoxicity in rats focused on changes in β-arrestin2 and molecular markers of neural injury in cerebral cortex.

methodsMale Wistar rats were subcutaneously injected with dexamethasone (10 mg/kg/day) for 7 days to induce neural injury in the cerebral cortex. The experiment involved 5 groups: control, dexamethasone, carvedilol, propranolol, and doxazosin. In the last 3 groups, drugs were given 2 hours before dexamethasone injection. At the end of experiment, brain samples were collected for measurement of brain derived neurotrophic factor (BDNF), glial fibrillary acidic protein (GFAP), kinase activity of protein kinase B (Akt), diacylglycerol (DAG), α-smooth muscle actin (α-SMA), Smad3, β-amyloid and phospho-tau protein levels in addition to histopathological examination of brain tissue using hematoxylin-eosin, Nissl, and Sirius red stains. Moreover, β-arrestin2 levels in the cerebral cortex were measured using immunohistochemical examination.

resultsDexamethasone slightly reduced brain weight and significantly decreased BDNF, Akt kinase activity and β-arrestin2 but markedly induced degeneration of cortical neurons and significantly increased GFAP, DAG, α-SMA, Smad3, β-amyloid and phospho-tau protein levels compared to controls. Carvedilol, propranolol, and doxazosin reversed all dexamethasone-induced molecular changes and slightly ameliorated the histopathological changes. Carvedilol significantly increased brain weight and β-arrestin2 levels compared to dexamethasone, propranolol, and doxazosin groups.

conclusionblocking α- and/or β-adrenergic receptors alleviate dexamethasone-induced neurotoxicity despite their distinct effects on β-arrestin2 levels in the cerebral cortex.

Indexed as

beta-Arrestin 2CarvedilolDexamethasoneAdrenergic AntagonistsAnimalsBiomarkersBrain-Derived Neurotrophic FactorCerebral CortexDoxazosinMaleNeurotoxicity SyndromesPropranololRatsRats, WistarAdrenergic Antagonistsbeta-Arrestin 2BiomarkersBrain-Derived Neurotrophic FactorCarvedilolDexamethasoneDoxazosinPropranololCarvedilolDexamethasoneDoxazosinNeurotoxicityPropranololβ-Arrestin2

Identifiers

PMID37966585
PMCPMC11087427
OpenAlexW4388699567

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.